In our pooled cohort, we observed a marked heterogeneity in tumour responses to anti-PD-1 drugs, ranging from complete remission to rapid disease progression after using ICIs [37,38,43], and that could have been related to several factors. This evidence concerns the gene PDCD1 and neoplasm.